Cataract Surgery during Anti-TNF-α Therapy (Infliximab) for Behçet’s Disease
|Department of Ophthalmology, Dokkyo Medical University, 880 Kitakobayashi Mibumachi, Shimotsugagunn, Tochigi 321-0293, Japan|
|Corresponding Author :||Shigenari Suzuki
Department of Ophthalmology
Dokkyo Medical University, 880 Kitakobayashi Mibumachi
Shimotsugagunn, Tochigi 321-0293, Japan
Tel: +81 282 86 1111 / 2675
Fax: +81 282 86 0630
E-mail: [email protected]
|Received December 02, 2011; Accepted February 05, 2012; Published February 12, 2012|
|Citation: Suzuki S (2012) Cataract Surgery during Anti-TNF-α Therapy (Infliximab) for Behçet’s Disease. J Clinic Experiment Ophthalmol S1:004. doi:10.4172/2155-9570.S1-004|
|Copyright: © 2012 Suzuki S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: In cases of complicated cataract due to Behçet’s disease, flare-ups of attacks of ocular inflammation tend to occur after cataract surgery. Because these flare-ups may often result in loss of vision in Behçet’s disease, attention is now being paid to complicated cataract surgery with the administration of infliximab, which provides powerful long-term suppression of attacks of ocular inflammation.
Case Report: Surgery was performed for complicated cataract due to Behçet’s disease with highly active uveitis in a patient who was being treated with infliximab. The patient was a 25-year-old man. Cataract surgery had been postponed due to highly active uveitis, but surgery was eventually performed while infliximab was being administered after the ocular inflammation had subsided as a result of this medication. The patient’s course was uneventful, with no postoperative flare-ups of ocular inflammation or infection.
Conclusion: Concomitant use of infliximab enables the safe performance of surgery for complicated cataract due to Behçet’s disease even in patients with highly active uveitis. And cataract surgery can be performed at any point during infliximab administration (5mg/kg) other than the induction period.